Equities Analysts Set Expectations for TMO Q2 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Investment analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of Thermo Fisher Scientific in a report issued on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $5.19 per share for the quarter, down from their previous estimate of $5.22. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q3 2025 earnings at $5.52 EPS, Q4 2025 earnings at $6.40 EPS, FY2025 earnings at $22.26 EPS, Q1 2026 earnings at $5.61 EPS, Q3 2026 earnings at $5.70 EPS, Q4 2026 earnings at $6.10 EPS, FY2026 earnings at $24.34 EPS and Q1 2027 earnings at $6.95 EPS.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the business posted $5.11 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year.

Several other research firms also recently weighed in on TMO. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Scotiabank decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research report on Friday, April 25th. Finally, Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $607.43.

Thermo Fisher Scientific Trading Down 0.1%

TMO opened at $413.47 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 1-year low of $390.50 and a 1-year high of $627.88. The company has a market cap of $156.08 billion, a P/E ratio of 25.01, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a fifty day moving average price of $449.99 and a two-hundred day moving average price of $508.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TMO. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $253,000. Intact Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 34.0% during the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after buying an additional 660 shares during the period. Purkiss Capital Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $1,121,000. Clear Harbor Asset Management LLC lifted its holdings in Thermo Fisher Scientific by 10.4% in the 4th quarter. Clear Harbor Asset Management LLC now owns 13,418 shares of the medical research company’s stock worth $6,981,000 after purchasing an additional 1,269 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Thermo Fisher Scientific by 11.6% during the 4th quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company’s stock worth $174,305,000 after purchasing an additional 34,917 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,075 shares of company stock worth $7,305,942. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.